secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celcuity Inc. (CELC)
CIK:        0001603454
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001493152-22-022062
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celcuity expands debt to $75M, Q2 net loss $10M, gedatolisib gets Breakthrough Therapy
--------------------------------------------------------------------------------

- Debt facility amended to up to $75M ($50M increase); $15M drawn, $20M due on private placement close; other tranches tied to clinical milestones.
- Q2 2022 net loss $10.0M ($0.67 loss per share) vs $14.0M ($1.11) in Q2 2021; non-GAAP adjusted loss $8.3M ($0.55).
- FDA granted Breakthrough Therapy designation in July for gedatolisib in HR+/HER2- metastatic breast cancer.
- Private placement of $100M equity signed May 2022; closing expected after first patient dosed in VIKTORIA-1.
- VIKTORIA-1 Phase 3 trial on track to dose first patient shortly; FACT-1/2 interim data expected mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/0001493152-22-022062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-022062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer